The 18 references in paper N. Nenasheva M., Н. Ненашева М. (2014) “Длительно действующие β2-агонисты в терапии бронхообструктивных заболеваний легких // Long-acting β2-agonists in treatment of obstructive lung diseases” / spz:neicon:pulmonology:y:2011:i:6:p:111-115

1
Anderson G.P. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2-adrenoceptor agonist bronchodilator. Life Sci.1993; 52 (26): 2145–2160.
(check this in PDF content)
2
Lotvall J.Pharmacological similarities and differences between beta2-agonists. Respir. Med. 2001; 95 (Suppl. B): S7–S11.
(check this in PDF content)
3
GINA, 2010. http:// www.ginasthma.com
(check this in PDF content)
4
Mitchell C., Jenkins C, Scicchitano R, Rubinfeld A. Adding formoterol is more effective and safer than doubling the dose of inhaled steroids in moderately severe asthma. Am. J. Respir. Crit. Care Med. 2000; 161: A197 (abstr.).
(check this in PDF content)
5
Black J.L., Oliver B.G.G., Roth M.Molecular mechanisms of combination therapy with inhaled corticosteroids and long-acting β-agonists. Chest 2009; 136: 1095–1100.
(check this in PDF content)
6
Grainge C, Lau L., Ward J. et al. Effect of bronchoconstriction on airway remodeling in asthma. N. Engl. J. Med. 2011; 364: 2006–2015.
(check this in PDF content)
7
Chowdhury B.A., Dal Pan G.The FDA and safe use of longacting beta-agonists in the treatment of asthma. N. Engl. J. Med. 2010; 362: 1169–1171.
(check this in PDF content)
8
GOLD, 2010.http:// www.goldcopd.com
(check this in PDF content)
9
Sears M.R. Long-acting bronchodilators in COPD. Chest 2008; 133: 1057–1058.
(check this in PDF content)
10
Rodrigo G.J., Nannini L.J., Rodriguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: A systematic review. Chest 2008; 133: 1079–1087.
(check this in PDF content)
11
Terzano C., Petroianni A., Conti V. et al.Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Res. Med. 2008; 102: 1701–1707.
(check this in PDF content)
12
Davies R.J., Stampone P., O'Conner B.J. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbone beclomethasone dipropionate at approximately half the total dose. Res. Med. 1998; 92 (Suppl. A): 23–31.
(check this in PDF content)
13
Gross G., Thompson P.J., Chervinsky P. et al. Hydrofluoroalkane-134a Beclomethasone Dipropionate, 400 mg, is as effective as chlorofluorocarbon Beclomethasone Dipropionate, 800 mg, for the treatment of moderate asthma. Chest 1999; 115 (2): 343–351.
(check this in PDF content)
14
Busse W.W., Brazinsky S., Jacobson K. et al.Efficacy response of inhaled beclomethasone dipropionat in asthma is proportional to dose and is improved by formulation with a new propellant. J. Allergy Clin. Immunol. 1999; 104: 1215–1222.
(check this in PDF content)
15
Цой А.Н.Фиксированная комбинация ультрамелкодисперсных дозированных аэрозолей беклометазона дипропионата / формотерола: слагаемые успеха. Consilium Medicum 2008; прил. "Болезни органов дыхания": 39–45.
(check this in PDF content)
16
Bousquet J., Huchon G., Leclerc V. et al. A randomized double-blind, double-dummy, single-dose efficacy crossover trial comparing Formoterol-HFA (pMDI) versus Formoterol-DPI (Aerolizer™) and placebo (pMDI or Aerolizer™) in asthmatic patients. Respiration 2005; 72 (Suppl. 1): 6–12.
(check this in PDF content)
17
Мещерякова Н.Н., Белевский А.С. Атмосфера. Пульмонол. и аллергол. 2007; 4: 32–35.
(check this in PDF content)
18
Backer W., Devolder A., Poli G. et al.Lung deposition of BDP / Formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J. Aerosol. Med. Pulm. Drug Deliv. 2010; 23 (3): 137–148. Информация об авторе
(check this in PDF content)